Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Treasury Shares (2023 - 2026)

MBX Biosciences has reported Treasury Shares over the past 4 years, most recently at $163562.0 for Q1 2026.

  • Quarterly results put Treasury Shares at $163562.0 for Q1 2026, up 1908.13% from a year ago — trailing twelve months through Mar 2026 was $163562.0 (up 1908.13% YoY), and the annual figure for FY2025 was $694.0, down 94.5%.
  • Treasury Shares reached $163562.0 in Q1 2026 per MBX's latest filing, up from $694.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $163562.0 in Q1 2026 and bottomed at $694.0 in Q4 2025.
  • Median Treasury Shares over the past 4 years was $10376.5 (2024), compared with a mean of $37620.4.
  • The largest annual shift saw Treasury Shares plummeted 94.5% in 2025 before it skyrocketed 1908.13% in 2026.
  • Over 4 years, Treasury Shares stood at $90324.0 in 2023, then crashed by 86.04% to $12608.0 in 2024, then tumbled by 94.5% to $694.0 in 2025, then surged by 23468.01% to $163562.0 in 2026.
  • Business Quant data shows Treasury Shares for MBX at $163562.0 in Q1 2026, $694.0 in Q4 2025, and $2514.0 in Q3 2025.